Payment overview · 2025
General Payments
$509.15
16 reported records · 11 companies
Healthcare provider profile · identity verified
Frank Bernard Ebai
Allopathic & Osteopathic Physicians|Internal Medicine · MESQUITE, TX · NPI 1902468796
Verified facts
What the public records show
CMS Open Payments records show Frank Bernard Ebai received $509.15 in general payments during 2025 across 16 reported records.
Lilly USA, LLC accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $152.29 | 29.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $121.84 | 23.9% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$73.00 | 14.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.75 | 5.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.93 | 5.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $22.02 | 4.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.29 | 4.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.28 | 3.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.57 | 3.5% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $16.34 | 3.2% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.84 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $509.15 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $107.48 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $44.81 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.75 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.93 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.93 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $12.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 117 |
| Gabapentin | Gabapentin | 191 | 86 |
| Lisinopril | Lisinopril | 183 | 74 |
| Metformin Hcl | Metformin Hcl | 182 | 83 |
| Losartan Potassium | Losartan Potassium | 163 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 48 |
| Carvedilol | Carvedilol | 115 | 47 |
| Furosemide | Furosemide | 110 | 48 |
| Tramadol Hcl | Tramadol Hcl | 107 | 43 |
| Nifedipine Er | Nifedipine | 102 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 52 |
| Ibuprofen | Ibuprofen | 99 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 99 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 41 |
| Ozempic | Semaglutide | 92 | 26 |
| Omeprazole | Omeprazole | 89 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 38 |
| Trazodone Hcl | Trazodone Hcl | 74 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 27 |
| Simvastatin | Simvastatin | 59 | 22 |
| Glipizide | Glipizide | 57 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 26 |
| Eliquis | Apixaban | 47 | 18 |
| Meloxicam | Meloxicam | 47 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 21 |
| Pregabalin | Pregabalin | 44 | 17 |
| Jardiance | Empagliflozin | 41 | 17 |
| Levetiracetam | Levetiracetam | 41 | 11 |
| Montelukast Sodium | Montelukast Sodium | 41 | 18 |
| Sertraline Hcl | Sertraline Hcl | 41 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 21 |
| Potassium Chloride | Potassium Chloride | 37 | 13 |
| Allopurinol | Allopurinol | 35 | 15 |
| Metformin Hcl Er | Metformin Hcl | 34 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 13 |
| Famotidine | Famotidine | 32 | 12 |
| Baclofen | Baclofen | 31 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Finasteride | Finasteride | 29 | 15 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 20 |
| Glimepiride | Glimepiride | 25 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 11 |
| Atenolol | Atenolol | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | 11 |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Lactulose | Lactulose | 19 | 12 |
| Spironolactone | Spironolactone | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $509.15 · 16 records | Lilly USA, LLC | AREXVY, BREZTRI, Fluad, Flucelvax, JARDIANCE, Korlym, Motpoly XR, Ocrevus Zunovo, Ozempic, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, Veozah, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error